U.S. FDA grants breakthrough therapy designation to Takeda’s investigational compound, TAK-994, an oral orexin agonist in clinical development for narcolepsy Type 1

Takeda

29 July 2021 - If approved, investigational TAK-994 may provide a future treatment option targeting the orexin deficiency underlying narcolepsy Type 1.

Takeda today announced that the U.S. FDA granted breakthrough therapy designation to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder